In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis, co-founder & CEO of Trenchant Bios, speaking live from the ISCT annual meeting. We dive into mesenchymal stem cells and induced pluripotent stem cells, exploring the science behind them, the manufacturing challenges, and the potential for scalable, engineered next-generation therapies.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJon Ellis, Co-founder & CEO, Trenchant BioMiguel Forte, President, International Society for Cell & Gene TherapyDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
Rethinking hair loss treatment
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
France’s biotech ecosystem: science, capital and scale
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.